Central serotonergic and dopaminergic actions are also known and may be responsible for occasional side effects, albeit with a very low incidence not different from placebo. [1, 2] Other substituted benzamides such as levosulpiride and metoclopramide are regularly associated with tremor and other extrapyramidal side effects likely due to their actions in presynaptic dopamine depletion and postsynaptic dopamine receptor blocking. [3, 4] Such drug-induced tremors may be due to striatal dopaminergic blockade and consequent oscillations in activity of the cortico-striato-thalamo-cortical loop. Tremor, Parkinsonism (often asymmetric), and tardive dyskinesias have all been reported with levosulpiride, with only 49% responding to drug cessation or medication. [5] In a study of 383 patients using cinitapride, jaw and head tremors were seen in only one patient, attributed to central dopaminergic blockade. [1] In another study, no neurological side effects were noted in 19 patients on long-term cinitapride. [2] The occurrence of tremor while performing complex tasks such as writing has not been noted after cinitapride use previously. The improvement in writing 6 months after cessation of cinitapride therapy supports a causative role for this medication in the genesis of the movement disorder. A drug challenge, which would have definitely established the causative nature of the association of the movement disorder to cinitapride use, was not performed as it was felt to be unethical.
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Sir, Myasthenia gravis (MG) is immunological disease of neuromuscular junction due to circulating antibodies. In generalized MG, 85% of patients are positive for acetylcholine receptor (AChR) antibodies, while 8%-10% of patients are positive for anti-MuSK antibodies. [1] Treatment of MG consists of symptomatic therapy with acetylcholinesterase inhibitors and immunotherapy such as corticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, plasmapheresis, and intravenous immunoglobulin (IVIG). [2] Between 10% and 15% of patients remain refractory to such treatment. Rituximab is newer immunosuppressive drug used recently for the treatment of refractory MG. [1] A 56-year-old male patient presented to a city hospital with weakness of facial muscles, drooping of eyelids, and slurring of speech since August, 2016. There, he was diagnosed to have MG with AChR antibody test positive (titer -30.8). Repetitive nerve stimulation test (RNST) showed significant decrement in amplitudes [ Figure 1 ]. Thymoma was not detected on contrast-enhanced computed tomography scan of thorax. He was started with pyridostigmine 30 mg twice daily dose, subsequently increased to 60 mg 4 times daily due to symptom aggravation. After 10 days, he was given IVIG (27 g/day) for 5 days at some other center, possibly due to rapid deterioration and apprehending that he may go into myasthenic crisis. Mycophenolate 500 mg daily and prednisolone 10 mg daily were started. After 1 month, due to progression of symptoms, 5 cycles of plasmapheresis were given. He showed significant improvement in symptoms for 4 days, after which symptoms reappeared.
Due to worsening of symptoms, he was referred to our center with severe bulbar weakness and difficulty in swallowing and speaking. AChR antibody titer was 19.60 nmol/L. Symptoms were suggestive of acute aggravation of myasthenia which was refractory to usual immunosuppressive treatment. Knowing that steroids may worsen symptoms during crisis and as the patient was rapidly deteriorating, dose of prednisolone was not increased. Hence, it was decided to treat him with rituximab. He was started on rituximab 500 mg intravenous infusion over 4 h on 2 days. Another dose of rituximab 500 mg IV infusion was repeated after 15 days for 2 more days. He showed improvement of symptoms within 4 days after 1 st infusion of rituximab. Mycophenolate which was started 2 months ago was tapered off within 1 month because of sustained improvement after rituximab infusion. He was discharged with advice to take pyridostigmine 30 mg 4 times daily. After 15 days follow-up, he showed improvement in symptoms. On follow-up in February, he showed further improvement with negative RNST and AChR titer of 12. Till date, after 7 months of 1 st infusion of rituximab, the patient is having sustained improvement.
Rituximab is a monoclonal anti-CD20 antibody that causes destruction of B cells by three mechanisms: antibody-dependent cellular cytotoxicity, [3] complement-dependent cytotoxicity, [4] and apoptosis. [4] In the recent study, MuSK-positive patients of MG treated with rituximab achieved higher rates of disease remission even after 1 st cycle of rituximab infusion and did not require repeated infusions whereas AChR-positive patients did not achieve complete remissions even after 2-3 cycles of rituximab. [5] However, in our case, the patient was AChR positive and achieved remission within 7 days of starting 1 st infusion of rituximab and maintained improved clinical status till date.
Rituximab can cause early and complete disease remission in AChR-positive refractory MG patients.
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